Mirion Technologies, Inc. - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring products and services for the medical, nuclear, and defense markets. The company operates through two reportable segments: Nuclear & Safety and Medical.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $266.8 million | $524.4 million |
| Gross Profit | $133.1 million (50.0% margin) | $252.2 million (48.1% margin) |
| Income from Operations | $17.9 million | $21.6 million |
| Net Income (GAAP) | $8.1 million | $4.7 million |
| Net Income Attributable to Mirion | $7.7 million | $4.3 million |
| Diluted EPS | $0.03 | $0.02 |
| Adjusted EBITDA | $65.3 million | $119.6 million |
| Cash and Cash Equivalents | $418.7 million | $418.7 million (Balance Sheet) |
| Total Debt (Non-Convertible) | $451.6 million | $451.6 million |
| Convertible Debt | $775.0 million | $775.0 million |
| Backlog | $1,138.6 million | $1,138.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 19.7% year-over-year for the quarter ($266.8M vs. $222.9M) and 23.4% for the six-month period ($524.4M vs. $424.9M). Growth was driven primarily by the Nuclear & Safety segment, which saw revenue increases due to recent acquisitions (Paragon and Certrec), price increases, and organic volume growth.
- Segment Performance:
- Nuclear & Safety: Q2 revenue rose to $186.2M (from $141.7M). Operating income increased to $26.0M (from $19.0M).
- Medical: Q2 revenue slightly declined to $80.6M (from $81.2M) due to volume declines in Asia-Pacific and dosimetry products, though operating income improved to $14.8M (from $10.9M) due to margin mix improvements.
- Net Income Volatility: While operating income improved, GAAP Net Income decreased slightly in the quarter ($8.1M vs. $8.5M) and significantly in the six-month period ($4.7M vs. $8.9M). This was primarily due to a $1.0M foreign currency loss in the current quarter compared to a $13.5M gain in the prior year, increased amortization from acquisitions, and higher stock-based compensation.
- Interest Expense: Net interest expense decreased significantly to $5.8M for the quarter (from $9.8M) due to lower SOFR rates and debt refinancing completed in the prior year.
Guidance, Outlook, and Risks
- Acquisition Integration: The company is integrating Paragon Energy Solutions (acquired Dec 2025) and Certrec (acquired July 2025), which are expected to drive future growth in the nuclear power and SMR markets.
- Geopolitical Risks: Significant exposure to geopolitical tensions involving Russia, China, and the Middle East. The company holds approximately $124.0 million in backlog related to Russian and Chinese projects. Sanctions and localization requirements remain key risks.
- Capital Allocation: The company continues a share repurchase program (up to $100M authorized). As of June 30, 2026, $59.6M has been spent, with approximately $40.4M remaining available.
- Debt Profile: The company maintains a $450M term loan and $175M revolving credit facility. It also holds $775M in convertible senior notes (2030 and 2031 maturities). The company is in compliance with all debt covenants.
- AI Initiatives: Management is investing in artificial intelligence functions, contributing to increased corporate SG&A expenses.
Investor Verification Checklist
- Acquisition Synergies: Verify the integration progress and revenue contribution of the Paragon and Certrec acquisitions against management's growth projections.
- Geopolitical Exposure: Assess the specific impact of ongoing sanctions on the $124M backlog related to Russia and China and the potential for contract cancellations or delays.
- Foreign Currency Impact: Monitor the volatility of the Euro/USD exchange rate, which caused a significant swing in non-operating income between periods.
- Convertible Debt Dilution: Review the conversion terms of the $775M in convertible notes and the associated capped call transactions to understand potential future dilution.
- Medical Segment Trends: Investigate the sustained decline in dosimetry sales and Asia-Pacific volume to determine if this is a temporary market fluctuation or a structural shift.